# A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

> **NCT04457180** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Apatinib Mesylate
- **DRUG:** Repaglinide
- **DRUG:** Bupropion

## Key facts

- **NCT ID:** NCT04457180
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-16
- **Primary completion:** 2021-05-20
- **Final completion:** 2021-06-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04457180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04457180, "A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04457180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*